Schwannomatosis

10/01/2015 - "Recent studies have demonstrated their frequent association with inherited syndromes like schwannomatosis and neurofibromatosis. "
11/01/2014 - "The aim of this study was to describe 3 cases of primary orbital schwannomatosis without associated systemic neurofibromatosis. "
11/19/2013 - "Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials."
11/19/2013 - "The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration was established with the goal to develop consensus recommendations for the use of endpoints in neurofibromatosis (NF) clinical trials. "
07/01/2015 - "Schwannomatosis is the third major form of neurofibromatosis (NF) and is distinct from NF1 and NF2. "

01/01/2013 - "The purpose of this study is to establish the feasibility of WB-MRI at 3T for lesion characterization, with DWI/ADC-mapping and contrast-enhanced sequences, in patients with neurofibromatosis type 2 (NF-2) and schwannomatosis. "
03/01/1998 - "The purpose of this study was to clarify the relationship between PS and the entities of neurofibromatosis 2 (NF-2; bilateral acoustic neurofibromatosis) and schwannomatosis. "
04/01/1997 - "Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study."
07/01/2015 - "It will be especially useful in differentiating schwannomatosis from mosaic Neurofibromatosis type 2 (NF2). "
06/01/2015 - "Schwannomatosis and neurofibromatosis type 2 are similar but different disease. "

03/01/2011 - "The aim of this study was to provide disease-specific information about schwannomatosis in its different forms and to present 2 particular cases of malignant schwannomas in the context of familial schwannomatosis (FS). "
11/25/2010 - "This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context."
07/01/2015 - "Schwannomatosis is characterized by the development of multiple non-vestibular, non-intradermal schwannomas. "
06/01/2015 - "Multiple Schwannomas of the Spine: Review of the Schwannomatosis or Congenital Neurilemmomatosis: A Case Report."
01/01/2015 - "Two cases of segmental sporadic schwannomatosis characterized by unusual location of multiple schwannomas in digital nerves (case 1) and the superficial radial nerve (case 2) are described in this paper. "

07/01/2015 - "In conclusion, our study demonstrates that molecular analysis of LZTR1 may contribute to the molecular characterization of schwannomatosis patients, in addition to NF2 mutational analysis and the detection of chromosome 22 losses in tumor tissue. "
03/01/2015 - "A rare case of schwannomatosis incidentally detected by ¹⁸F-FDG PET/CT during metabolic evaluation of a chest wall tumor."
01/01/2015 - "Accurate cell lines derived directly from human tumors will serve as invaluable tools for advancing schwannomatosis research, including drug screening. "
01/01/2015 - "No differences in key genes were detected, with the exception that several cell cycle regulators were upregulated in the schwannomatosis cell lines when compared to their parent tumors. "
01/01/2015 - "Therefore we took on the challenge of creating immortalized human Schwann cell lines derived from tumors from schwannomatosis patients. "

08/25/2007 - "[Familial schwannomatosis, a new entity distinct from neurofibromatosis type 1 and 2]."
06/01/2007 - "Recognizing schwannomatosis and distinguishing it from neurofibromatosis type 1 or 2."
04/01/1996 - "Rare cases have been associated with "schwannomatosis" as well as type 1 neurofibromatosis (von Recklinghausen's disease). "
09/01/2013 - "The aim of this study was to review the literature on quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis, and to identify the specific aspects of quality of life that were studied and reported in this population. "
10/01/2014 - "The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study."